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Abstract: Community pharmacy services have evolved to include medical and pharmaceutical
interventions alongside dispensing. While established pharmacogenomic (PGx) testing is available
throughout the Netherlands, this is primarily based in hospital environments and for specialist
medicines. The aim of this work was to describe how best to implement PGx services within
community pharmacy, considering potential barriers and enablers to service delivery and how to
address them. The service was implemented across a selection of community pharmacies in the
Netherlands. Data were captured on test outcomes and through a pharmacist survey. Following
testing, 17.8% of the clinical samples were recommended to avoid certain medication (based on their
current medicines use), and 14.0% to have their dose adjusted. Pre-emptive analysis of genotyped
patients showed that the majority (99.2%) had actionable variants. Pharmacists felt confident in their
operational knowledge to deliver the service, but less so in applying that knowledge. Delivering
the service was believed to improve relationships with other healthcare professionals. These results
add to the evidence in understanding how PGx can be delivered effectively within the community
pharmacy environment. Training pharmacists in how to respond to patient queries and make clinical
recommendations may enhance service provision further.
Keywords: community pharmacy; implementation; medicines optimization; pharmacogenomics
1. Introduction
The use of pharmacogenomics (PGx) to support a personalized medicines approach
can help improve patient safety and lead to better outcomes for patients. Not only does
PGx provide clinical benefits, but it has also been demonstrated to have a positive impact
on health costs, with the potential to be cost-effective or cost-saving [1]. Testing has
historically been in specialist areas where there are narrow therapeutic windows with
serious clinical consequences as a result of mismatched gene–drug pairings. Although
most medicines prescribed in primary care may not be considered high risk, the overall
prescription volumes of those that are, in combination with high frequency of actionable
phenotypes, results in a high potential global impact. Within the Netherlands, a recent
estimation of the impact of pre-emptive PGx testing of a panel of 45 drugs indicated that
23.6% of all new prescriptions were linked to an actionable gene–drug interaction (GDI) [2].
The potential to use PGx testing to tailor medicines usage is a natural fit for community
pharmacy, where medicines optimization is a key offering of pharmacists through services
such as the New Medicines Service in the United Kingdom (UK) [3].
Pharmacy 2021, 9, 38. https://doi.org/10.3390/pharmacy9010038 https://www.mdpi.com/journal/pharmacy
Pharmacy 2021, 9, 38 2 of 9
While PGx testing laboratories have been set up across many countries, the practice
is not yet embedded into routine care across community and hospital settings. Attempts
are being made to develop its use; for example, the UK has set up a National Genomics
Medicine Service with the aim to integrate genomic medicine into routine National Health-
care Service care by 2025 [4]. The Netherlands is one of the most advanced in this area,
helped by a healthcare system setup around a single, central drug database (G-Standaard)
that provides a supportive infrastructure for national testing programs [5]. In 2005, a
specialist laboratory was set up to provide national testing facilities at the University of
Rotterdam [6] and the ‘Dutch Pharmacogenetics Working Group’ (DPWG) was formed [7].
The DPWG develop PGx-based therapeutic (dose) recommendations, which they have for
over 80 drugs, and is updated every three months [8]. Recommendations appear as clinical
decision support alerts whenever a medicine that can be informed by PGx is prescribed or
dispensed.
Work is ongoing to establish the optimal model for implementing PGx testing into
healthcare systems: whether to use a pre-therapeutic single gene approach (historically
used), or pre-emptive panel-based approach; who should lead on the testing; in what
setting (community or hospital); and finally, whether to use the DPWG or the US-developed
Clinical Pharmacogenetics Implementation Consortium (CPIC) recommendations [9], or
a combination of the two. Efforts to harmonize DPWG and CPIC recommendations are
underway [10], but further research is needed to explore these other issues, particularly on
the practical aspects of delivery.
The first randomized controlled trial to use a panel-based approach, PREemptive Phar-
macogenomic testing for prevention of Adverse drug Reactions (PREPARE), is ongoing at
multiple sites across Europe [11], but results have not yet been reported. There have been a
small number of pilot services evaluating panel-based PGx testing in the community phar-
macy setting. The Royal Dutch Pharmacist Association pilot [12] and the Implementation
of Pharmacogenetics into Primary care Project (IP3 study) [13,14] were both conducted in
the Netherlands and found that between 24% and 31% of tests resulted in action being
taken (total 215 and 200 patients respectively, tests were provided free for the patient).
In the US, a study across six primary care settings (including one pharmacy) identified
96.8% of the 189 patients had at least one actionable phenotype for medications linked
to the decision support software, which was then subsequently used to aid medication
decisions 236 times by physicians and pharmacists over a period of three months [15].
Limited experience in community pharmacies in other countries has been reported [16].
To enable healthcare professionals to adopt and implement new services of this na-
ture effectively, it is important that all barriers are identified and addressed, and enablers
appropriately used. The aims of this service evaluation were to describe the initial PGx out-
comes from the service, the proportion of test results which could be used to inform future
prescribing and identify whether potential barriers and enablers had been appropriately
addressed or used to optimize service delivery from the perspective of the community
pharmacist.
2. Materials and Methods
2.1. Study Design
The study is a service evaluation based on a novel service set up across a network
of community pharmacies in the Netherlands between 2019 and 2020. The survey was
designed in England with collaborators from the Netherlands, with data managed and
quality assured through the use of anonymized data and collation on a centralized database.
2.2. Service Implementation
Community pharmacists that were part of a network were invited to take part in
the service through local communication channels and networks. Pharmacists across
18 pharmacies attended training during November 2019, and staff across an additional
60 pharmacy sites were trained in February 2020. All pharmacists participating in the
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service were required to complete the online training provided by KNMP (“Do you already
have your DNA passport?” and “Pharmacogenetics: from basics to expertise”) [17], fol-
lowed by a half day workshop which covered additional information on PGx delivered by
a medical expert, covering local guidelines, operational and logistical aspects of the service.
Pharmacists engaged with local doctors to raise awareness of the service; offering them the
chance to ask any questions, and to arrange methods of communication for any patient
results. Local doctors, pharmacists and their healthcare teams were also able to experience
the test themselves for free (herein known as educational tests) to enable them to better
understand the process and its potential value for patients.
Suitable patients could be identified by pharmacists, referred into the service by local
doctors, or were able to request the service themselves within the pharmacy (marketing
materials were available within the pharmacy itself). The service took place inside a
consultation room within the pharmacy, where pharmacists entered test details such as
sample ID, date of birth, gender, ethnicity and medication use (optional) onto the OneOme
testing portal. DNA samples were collected from participants using the OraCollect®
DNA collection kit (DNA Genotek, Ottawa, Ontario, Canada), and informed consent was
obtained from all participants. Samples were sent to OneOme for testing (Minneapolis, MN,
USA). The RightMed pharmacogenomic test was run on the samples using TaqMan® SNP
Genotyping, (Thermo Fisher Scientific, Waltham, MA, USA) and copy number variation
on a qPCR IntelliQube® qPCR platform (Douglas Scientific, Alexandria, MN, USA). All
genotyping and PGx interpretation were conducted in a Clinical Laboratory Improvements
Amendments (CLIA) and College of American Pathologists (CAP) accredited environment.
Each participant received the RightMed Comprehensive test report, which provides PGx
interpretation for 27 genes (111 alleles) and guidance on more than 300 medications.
Recommendations from the test outcome were based on local guidelines within the
Netherlands [8], alongside a more detailed report which included additional information
based on evidence and guidelines from other countries [9]. Results were returned to the
pharmacy within one to two weeks via the OneOme portal. Pharmacists then consulted
with the patients directly to discuss the outcomes and communicated with the patients’
doctor regarding any potential medication changes. A copy of the summary and full test
report was given to the patient directly and uploaded to their medication record; available
to healthcare practitioners involved in their care to help inform medicines related decisions.
Anonymized genotype data for genetic variants tested by the OneOme PGx panel
were analysed to calculate the frequency at which actionable variants occurred. This
was used to estimate potential impact of the OneOme PGx panel on the Dutch primary
care population.
2.3. Service Evaluation Methods
Volumes of overall tests undertaken were recorded on the OneOme testing portal,
which were labelled as either educational (undertaken on doctors and pharmacists) or
clinical (undertaken on patients). To support service evaluation and improvement, pharma-
cists were asked to record additional information onto the OneOme portal when patients
returned to the pharmacy after testing with any subsequent prescriptions. This was to
allow for enough time for any changes to the prescription to be made following the PGx
test. Data were collected on demographics (age, ethnicity, gender), reason for test, test
outcome, how the patient accessed the test, why they undertook it, and outcome of the
recommendation to the doctor (whether medication was altered and if so how).
Pharmacists participating in the service were invited to complete a survey two to six
months after service commencement. The survey was designed to identify barriers and
enablers to service implementation from the perspective of the pharmacist. Questions were
included to explore feedback on training, motivation for providing the service, preparation
for the role, impact on relationships with other healthcare providers, perceived patient
benefits, outcomes following the test, and delivery of the service. Responses to survey
questions were categorical (yes/no; multiple choice), ordinal (five-point Likert scale)
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and free-form text. The survey was translated into Dutch before sending electronically
to pharmacists.
2.4. Data Analysis
Anonymized data were entered onto Microsoft Excel© 365, translated back to English
where necessary, and analysed descriptively. Categorical and ordinal data were presented
as numbers and percentages as appropriate. The five-point Likert scales were amalgamated
to three to simplify data presentation where appropriate.
3. Results
3.1. Testing Results
From September 2019 to June 2020, a total of 611 tests were undertaken across 22 phar-
macies (207 clinical (patients), 404 educational (healthcare professionals)). Demographic
and outcomes data were recorded by the pharmacists for 107 patients of the clinical tests
(51.7%). While not the main focus of this evaluation, data were also available for 148
(36.6%) of the educational tests. Just over half (56.1%, n = 60/107) of the clinical sample
were female, with an average age of 59.5 years (range 5 to 87), and 91.6% (n = 98/107) were
white or Caucasian (remainder unknown). For the educational sample, 68.9% (n = 102/148)
were female, with an average age of 46.7 years (range 17 to 84), and of the known data, all
(n = 65/65) were white or Caucasian (remainder unknown n = 83).
Over half the patients (52.3%, n = 56/107) approached the pharmacist directly to
request the test, 24.3% (n = 26/107) were recommended by the pharmacist to have the
test, and 23.4% (n = 25/107) recommended by their doctor. The majority of reasons for
requesting the test were due to concern regarding adverse drug reactions or pre-emptive to
optimise initial therapy selection (Table 1).
Table 1. Reason for test (clinical sample, n = 107).
Reason for Test Count Percentage
Previous/current adverse drug event 29 27.1%
Pre-emptive 25 23.4%
Other 17 15.9%
Psychiatric condition 14 13.1%
Cardiovascular condition 12 11.2%
Polypharmacy 5 3.7%
High-risk medication (s) 4 3.7%
Oncologic condition 1 0.9%
Total 107 100%
Following testing, 17.8% (n = 19/107) of the clinical samples were recommended to
avoid certain medication (based on their current medicines use), and 14.0% (n = 15/107) to
have their dose adjusted (no change for 68.2%, n = 73/107). The majority of recommen-
dations were actioned by the prescriber resulting in a change to the patient’s prescription
(82.4%, n = 28/34).
For the educational results, the majority of the sample recorded the reason for taking
the test as other (due to the fact that it was part of attending the training course, or
engagement with local healthcare professionals, 80.4%, n = 119/148), or as pre-emptive
(14.9%, n = 22/148). A small number of individuals (4.7%, n = 7/148) took the test for
clinical reasons. Following testing, 8.8% (n = 13/148) of the sample were recommended to
avoid certain medication (based on current use), and 4.7% (n = 7/148) to have their dose
adjusted (no change for the remainder). A third of this sample had their prescriptions
altered as a result of the test (30.0%, n = 6/20).
The OneOme panel identified one or more actionable variants in 99.2% of the geno-
typed patients in the sample (n = 618). Furthermore, 90.9% of patients had two actionable
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PGx variants and 57.1% had three actionable PGx variants. Only 1.6% of patients had no
actionable variants for CYP2D6, CYP2C9, CYP2C19, SLCO1B1, and VKORC1 genes.
3.2. Pharmacist Survey
The survey was completed by 22 pharmacists (managers and/or owners) during
June 2020, when they had been providing the service for an average of 27.6 weeks (range
9–64 weeks). Primary reasons for providing the service included being able to personalize
patients’ medication (22.7%, n = 5), the innovative nature of the service (22.7%, n = 5),
developing the profession (18.2%, n = 4), personal interest (13.6%, n = 3), patient need
(9.1%, n = 2), commercial value (9.1%, n = 2), and being able to widen services on offer
within that pharmacy (4.5%, n = 1).
The majority of pharmacists (86.4%, n = 19) agreed that they had sufficient knowl-
edge and background information about PGx following the training and workshops (two
disagreed and one was neutral). Pharmacists felt that they had sufficient knowledge in
operational aspects of service delivery (introducing the test to patients, taking the swab,
and registering details), but less so in applying that knowledge (responding to questions
from patients, assessing the report and making recommendations, and discussing results
with doctors) (Table 2).
Table 2. Level of pharmacists’ agreement with having sufficient knowledge following the training
(n = 22).
Area of Knowledge Agreed/Strongly Agreed Neutral Disagreed
Introduce the PGx test to patients 18 (81.8%) 3 (13.6%) 1 (4.5%)
Respond to concerns and/or
questions from patients 12 (54.5%) 8 (36.4%) 1 (4.5%)
Take the swab 21 (95.5%) 1 (4.5%) 0 (0.0%)
Register and send the swab online 19 (86.4%) 2 (9.1%) 1 (4.5%)
Assess report and make
recommendations 10 (45.5%) 9 (40.9%) 3 (13.6%)
Discuss the results with a doctor 15 (68.2%) 4 (18.2%) 3 (13.6%)
Pharmacists offered free educational tests to doctors as part of early engagement plans,
of which a third of pharmacists responding to the survey (31.8%, n = 7) said that all the
doctors they regularly worked with had used the test, over half (54.5%, n = 12) said that
some of the doctors had used it, and 13.6% (n = 3) said none had. A quarter of pharmacists
(27.3%, n = 6) felt that doctors supported use of the test with patients, 45.5% (n = 10) were
neutral, and 27.3% (n = 6) stated that they disagreed with its use.
Pharmacists communicated results of the tests with the patients’ doctor via several
methods, the most frequent being face to face (45.0%, n = 9) or via email (35.0%, n = 7). Only
three pharmacists (15.0%) were able to update the patient’s medical record directly. Other
methods of communication used included via the patient (n = 3), and via post (n = 2).
Half of pharmacists (54.5%, n = 12) stated that offering the service had helped them
improve the relationship they have with other healthcare providers, 22.7% (n = 5) were not
sure, and the same said that it had not (n = 5). The majority of pharmacists had received
mainly positive feedback from doctors (86.7%, n = 19), with the remaining not having any
feedback at the time of the survey.
When pharmacists recruited patients directly, uptake of the service varied (nine
pharmacists stating 0–50% uptake, nine pharmacists had 51–100% uptake, four unknown);
with three-quarters of pharmacists (n = 17) stating that the main reason patients did not
take up the test was due to the cost.
Over half of the pharmacists (n = 14) reported that patients had given them positive
feedback about the service (nil responses from the other pharmacists). Pharmacists per-
ceived the main benefits of the service to be around supporting medicines optimization,
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and in particular more targeted (n = 13) and appropriate therapy on drug initiation (n = 11)
with fewer side effects (n = 14).
4. Discussion
This evaluation showed that one in six patient tests resulted in recommendations
to stop current treatment and one in seven to change the current dose (of which almost
all changes were subsequently implemented by the prescriber). This is in line with the
higher end of previous studies within the Netherlands, but is understandable given the
extended testing panel and evolution of additional evidence over time [12–14]. Nearly all
patients received a result which could be used to inform future prescribing decisions, and
consequently it could be argued that provision of access to such a service is likely to provide
benefit to a significant proportion of patients in the future. The value of pre-emptive testing
has started to be more widely recognized, with the UK strategy having recently been
announced whereby it will be part of routine care attached to medical records to guide
therapeutic decision making in the next ten years [18]. Regardless of when, where and
why the initial test was carried out, the long-term value to the patient will come from all
healthcare professionals using that information to guide any future prescribing decisions.
Pharmacists delivering the service, local doctors, and healthcare teams were offered
the test for educational purposes, to enable them to understand the logistics and process
for implementation and the potential benefits of the service from a personal perspective.
Teams local to the pharmacies were offered the service for purposes of promotion and
to encourage referrals but also to enhance social influence, i.e., increase the likelihood of
doctors being supportive of the new service. The majority of the educational tests were pre-
emptive and not based on clinical need, and as a result, the numbers with recommended
changes to medicines were much lower than that seen in the clinical tests.
The training provided pharmacists with sufficient knowledge to be able to opera-
tionally deliver the service, although a proportion felt less equipped to be able to respond
to questions from patients, assess the report and make recommendations, including dis-
cussing these with doctors. The perceptions of local doctors’ response to the provision
of PGx was, however, less positive, with only a quarter believing that the majority of
doctors were supportive (although half were also perceived as neutral). Interestingly, how-
ever, more than half of the pharmacists reported that the service had improved working
relationships with local doctors, and most had experienced positive feedback.
Over half of the patients approached the pharmacists directly to enquire about under-
taking the test, motivated by specific clinical needs. Despite the high cost in comparison
to other services on offer within the pharmacy, patients appeared willing to pay; placing
high value on the information to inform choice of therapy. This was also the case when
referred directly by the doctor, or by the pharmacist themselves, with high numbers of
those recommended the service taking it up, potentially demonstrating trust in the advice
from both healthcare professionals. Cost, however, was perceived by pharmacists to be the
biggest barrier to uptake by patients who were recommended the service and chose not to
participate despite patients being used to paying for access to healthcare (through monthly
premiums, deductible fees, and consultations with doctors). These findings are similar to
previous research that found that the majority of patients would only undertake testing
if reimbursed, despite being interested and valuing the test [19]. This may be more of an
issue in countries where healthcare is free at the point of care.
The lack of understanding of PGx has been a commonly reported problem [20], with
many healthcare professionals’ perception of the complexity of the application being cited
as a barrier to uptake [21]. Healthcare professionals working collaboratively across settings
to support patients with their health and medical needs has been found to benefit patient
outcomes and deliver value to the healthcare system [22], but use of technology to allow
this (namely electronic transfer of health data between settings) has been reported to
be of limited interest to health authorities and not widely used among pharmacies [23].
Within the evaluation of this service, most of the pharmacists said that they had received
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positive feedback from doctors, and it had helped them improve the relationships they
had with them more generally, as found in other studies where pre-existing relationships
exist [24]. Very few pharmacists had the ability to upload the results of the test directly
onto the patients’ health records, which could then be used for future medicine related
decisions by all prescribers. The ability for community pharmacists to use and access health
records is something that is progressing across many countries [25], allowing more effective
communication between healthcare settings. Participating pharmacists were, however,
able to follow patients up when they came into the pharmacy for subsequent prescriptions,
checking on any changes that were made to their medication, and reinforcing advice and
medicines usage. Using pharmacists’ expertise to support medicine optimization provides
an opportunity to build on these working relationships more effectively and allows doctors
to recognize the value that pharmacists can bring in supporting patient care. Without
this partnership approach, the value of the test will not be realized in following through
medication recommendations and monitoring changes.
Given the backdrop of widespread PGx services across hospitals in the Netherlands, it
is not surprising that the majority of pharmacists in the analysis were interested in getting
involved as a way of expanding their professional role in providing innovative services.
While these pharmacists perceived PGx as a natural extension to their role in supporting
medicines optimization, levels of confidence and knowledge of pharmacists in countries
where PGx testing is not established in the setting have been reported to be low [26–28].
Limitations
Due to COVID-19, PGx-related activities within community pharmacies were reduced
from March to June 2020, and therefore the number of patients in receipt of the service in
each pharmacy per month was relatively low. Additional demographic and outcomes of the
service data were collected as part of the evaluation when patients returned to the pharmacy,
and hence were not available for all service users. In comparison, the large number of
tests undertaken for educational reasons reflects that this evaluation was at an early stage,
where community pharmacists and the local doctors were being introduced to the new
technology. While education regarding pharmacogenomics is a significant element of
pharmacist development within the Netherlands, the selection of community pharmacists
may also not be wholly representative of the community at large as they were selected
based on their interest in providing the service and may therefore be more proactive than
other pharmacists. A later evaluation may provide a more accurate picture with respect
to demand and the consequences of any prescription modifications (treatment effect, etc.).
The survey was not piloted or validated, and the questions were developed by the team
who made assumptions as to what the barriers were likely to be and therefore may not
have captured all individual or environmental elements related to service implementation
or effectiveness. Further qualitative work is warranted to better understand the barriers
and enablers to service provision from the perspective of all stakeholders (with patient and
doctor perceptions being indirectly reported through pharmacists’ responses). Pharmacists
were responsible for only a quarter of all tests, and although the service was delivered
through them, research to identify barriers and enablers associated with direct patient
access and physician referral is warranted. Like all healthcare services, the impact of
COVID-19 affected our ability to follow up with additional patients when they presented
in the pharmacy, thereby limiting the number of longitudinal data points.
5. Conclusions
Each country looking to implement PGx testing will have a different set of criteria
for patient and drug eligibility based on health economic value to healthcare funders, and
for where the test itself is conducted (be it within community of hospital environments).
The importance of ensuring that regardless of why and where the test was conducted,
the results should be used by all healthcare professionals and across all settings going
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forward to support optimum medicines use, providing longer term value to the patient
and healthcare system.
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